Trial Profile

Multi-center, Open, Dose-escalation, and Expanded Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JAB-21822 in Advanced Solid Tumors With KRAS p.G12C Mutation

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glecirasib (Primary)
Indications Adenocarcinoma; Appendiceal cancer; Biliary cancer; Carcinoma; Cervical cancer; Colorectal cancer; Ductal carcinoma; Gastric cancer; Liver cancer; Mediastinal disorders; Non-small cell lung cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Peritoneal cancer; Solid tumours
Focus Adverse reactions; First in man; Registrational; Therapeutic Use
Sponsors Allist Pharmaceuticals

01 Mar 2025 Results (n=119, As of the data cut-off date on 28 March 2024) published in the Nature Medicine.
12 Jun 2024 Planned number of patients changed from 144 to 311.
12 Jun 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com